Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus TACE for locally advanced stomach adenocarcinoma
NCT04799548Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2021
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in gastric adenocarcinoma, sponsored by Zhongshan Hospital, Fudan University. Started Dec 2021; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04799548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04799548.